Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of HFA-152a vs HFA-134a Propellant in Mild Asthma
NCT05472662Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Test (Placebo HFA-152a) with Reference (Placebo HFA-134a) (2 arms). Primary endpoint: Relative Change From Baseline in Forced Expiratory Volume in 1 Second at 15 Minutes Post-dose. Started Aug 2022; status: completed.
02
Drugs
HFA-152a
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05472662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472662.